These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Mutation in TET2 in myeloid cancers. Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426 [TBL] [Abstract][Full Text] [Related]
6. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. Kohlmann A; Grossmann V; Klein HU; Schindela S; Weiss T; Kazak B; Dicker F; Schnittger S; Dugas M; Kern W; Haferlach C; Haferlach T J Clin Oncol; 2010 Aug; 28(24):3858-65. PubMed ID: 20644105 [TBL] [Abstract][Full Text] [Related]
7. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Ko M; Huang Y; Jankowska AM; Pape UJ; Tahiliani M; Bandukwala HS; An J; Lamperti ED; Koh KP; Ganetzky R; Liu XS; Aravind L; Agarwal S; Maciejewski JP; Rao A Nature; 2010 Dec; 468(7325):839-43. PubMed ID: 21057493 [TBL] [Abstract][Full Text] [Related]
8. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. Makishima H; Cazzolli H; Szpurka H; Dunbar A; Tiu R; Huh J; Muramatsu H; O'Keefe C; Hsi E; Paquette RL; Kojima S; List AF; Sekeres MA; McDevitt MA; Maciejewski JP J Clin Oncol; 2009 Dec; 27(36):6109-16. PubMed ID: 19901108 [TBL] [Abstract][Full Text] [Related]
9. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Beer PA; Delhommeau F; LeCouédic JP; Dawson MA; Chen E; Bareford D; Kusec R; McMullin MF; Harrison CN; Vannucchi AM; Vainchenker W; Green AR Blood; 2010 Apr; 115(14):2891-900. PubMed ID: 20008300 [TBL] [Abstract][Full Text] [Related]
10. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Abdel-Wahab O; Mullally A; Hedvat C; Garcia-Manero G; Patel J; Wadleigh M; Malinge S; Yao J; Kilpivaara O; Bhat R; Huberman K; Thomas S; Dolgalev I; Heguy A; Paietta E; Le Beau MM; Beran M; Tallman MS; Ebert BL; Kantarjian HM; Stone RM; Gilliland DG; Crispino JD; Levine RL Blood; 2009 Jul; 114(1):144-7. PubMed ID: 19420352 [TBL] [Abstract][Full Text] [Related]
11. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Jankowska AM; Szpurka H; Tiu RV; Makishima H; Afable M; Huh J; O'Keefe CL; Ganetzky R; McDevitt MA; Maciejewski JP Blood; 2009 Jun; 113(25):6403-10. PubMed ID: 19372255 [TBL] [Abstract][Full Text] [Related]
12. Mutations in chronic myelomonocytic leukemia and their prognostic relevance. Jian J; Qiao Y; Li Y; Guo Y; Ma H; Liu B Clin Transl Oncol; 2021 Sep; 23(9):1731-1742. PubMed ID: 33861431 [TBL] [Abstract][Full Text] [Related]
13. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies. Lv K; Jiang J; Donaghy R; Riling CR; Cheng Y; Chandra V; Rozenova K; An W; Mohapatra BC; Goetz BT; Pillai V; Han X; Todd EA; Jeschke GR; Langdon WY; Kumar S; Hexner EO; Band H; Tong W Genes Dev; 2017 May; 31(10):1007-1023. PubMed ID: 28611190 [TBL] [Abstract][Full Text] [Related]